Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329 · View on ClinicalTrials.gov ↗
Study Summary
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG disitamab vedotin
Study Locations (20)
California
- Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim
- Foothill Cardioology — Arcadia
- Kaiser Permanente Baldwin Park Medical Center — Baldwin Park
- Kaiser Permanente Bellflower Medical Offices — Bellflower
- Beverly Hills Multi-Specialties Practice — Beverly Hills
- Providence Saint Joseph Medical Center — Burbank
- UCLA Burbank Cardiology — Burbank
- UCLA Hematology/Oncology - Burbank — Burbank
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte
- UCLA Encino Specialty Care (Radiology) — Encino
- UCLA Hematology/Oncoclogy-Encino — Encino
- Kaiser Permanente Fontana Medical Center — Fontana
- Foothill Cardiology Glendora — Glendora
- Kaiser Permanente South Bay Medical center — Harbor City
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine
- Kaiser Permanente Alton/Sand Canyon Medical Offices — Irvine
- UCLA Downtown Los Angeles Primary & Specialty Care — Los Angeles
- Kaiser Permanente Los Angeles Medical Offices — Los Angeles
Arizona
- Banner Gateway Medical Center — Gilbert
- Banner MD Anderson Cancer Center — Gilbert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2029-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04879329
The ClinicalTrials.gov registry entry for NCT04879329 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions — of which pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04879329 reports 20 study locations spanning 2 distinct geographic areas — top geographies include California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04879329 about?
NCT04879329 is a clinical study titled "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2". This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanc...
What is the current status of trial NCT04879329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 372 participants. The study started on 2022-05-03. Estimated completion is 2029-04-14.
What conditions does trial NCT04879329 study?
This clinical trial studies the following conditions: Urothelial Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04879329?
The interventions under investigation include: pembrolizumab (DRUG), disitamab vedotin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04879329?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04879329 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.